Home Temperature-responsive and biodegradable PVA:PVP k30:poloxamer 407 hydrogel for controlled delivery of human growth hormone (hGH)
Article
Licensed
Unlicensed Requires Authentication

Temperature-responsive and biodegradable PVA:PVP k30:poloxamer 407 hydrogel for controlled delivery of human growth hormone (hGH)

  • Azade Taheri , Fatemeh Atyabi and Rassoul Dinarvnd EMAIL logo
Published/Copyright: April 14, 2011

Abstract

Recombinant human growth hormone (rhGH) is used for replacement therapy of pediatric hypopituitary dwarfism. Growth rate in children was observed to be better on the daily injection schedule compared with the currently used therapeutic regimen of thrice a week injection. Thus, a controlled release formulation would overcome the drawback of traditional rhGH therapy such as the need for multiple injections. Poloxamers are a family of triblock copolymers consisting of two hydrophilic blocks of polyoxyethylene separated by a hydrophobic block of polyoxypropylene, which form micelles at low concentrations and form clear thermally reversible gels at high concentrations. We used poloxamer gels to develop a controlled release formulation of hGH. The objective of this study was to develop an in situ gel forming drug delivery system for hGH using the minimum possible ratio of poloxamer 407 (P407). Decreasing the concentration of poloxamer could reduce the risk of hypertriglyceridemia induction. Different additives were added to the poloxamer formulations. It was observed that among different additives polyvinylpyrrolidone k30 (PVP k30) and polyvinyl alcohol (PVA) decrease poloxamer concentration required to form in situ gelation from 18% to 10%. The dynamic viscoelastic properties of the samples were determined. Both the storage modulus and the loss modulus of the samples increased abruptly as the temperature passed a certain point. It can be concluded that combining P407 and PVP and PVA could be a promising strategy for preparation of thermally reversible in situ gel forming delivery systems of hGH with low poloxamer concentration.


Corresponding author: Rassoul Dinarvand, PhD, Professor of Pharmaceutics, Dean, Faculty of Pharmacy, Tehran University of Medical Sciences, PO Box 14155-6451, Tehran, Iran Phone: +98-21-66959095, Fax: +98-21-66959096

Published Online: 2011-04-14
Published in Print: 2011-04-01

©2011 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Publisher’s Note
  2. Publisher’s Note
  3. Editorials
  4. What brings a child to the doctor? A lesson from hyperthyroidism
  5. Images in Pediatric Endocrinology
  6. Hypothalamic hamartoma causing precocious puberty in a female child
  7. Original Contributions
  8. Adiponectin moderates the relationship between adiposity and leptin in adolescents regardless of gender or race
  9. Obesity in children and adolescents: relationship to growth, pubarche, menarche, and voice break
  10. Studies of different female rat models of hypothalamic obesity
  11. Frequency of congenital hypothyroidism in neonatesin the Konya region, Turkey
  12. Thyroid dysfunctions in children detected in mass screening for congenital hypothyroidism
  13. A nutritional intervention study with hydrolyzed collagen in pre-pubertal Spanish children: influence on bone modeling biomarkers
  14. Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone
  15. Evidence of insulin-like growth factor binding protein-3 proteolysis during growth hormone stimulation testing
  16. Pediatric 25-hydroxyvitamin D concentrationsin neurofibromatosis type 1
  17. Temperature-responsive and biodegradable PVA:PVP k30:poloxamer 407 hydrogel for controlled delivery of human growth hormone (hGH)
  18. Patient Report Letters
  19. A novel EIF2AK3 mutation leading to Wolcott-Rallison syndrome in a Chinese child
  20. Neurological Wilson’s disease with refractory rickets
  21. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes
  22. Pediatric Cushing’s disease due to pituitary hyperplasia
  23. A 12-year-old Chinese girl with Cushing syndrome and virilization due to adrenocortical carcinoma
  24. Primary pigmented nodular adrenocortical disease: a case report in a 7-year-old girl
  25. Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure
  26. Transient hyperthyroidism due to acute suppurative thyroiditis in an adolescent female
  27. High frequency of cardiac and behavioral complaints as presenting symptoms of hyperthyroidism in children
  28. Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero
  29. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion in a 3-year-old child
  30. Familial occurrence of Turner syndrome: casual event or increased risk?
  31. Mature teratoma, a rare cause of virilization in adolescence
  32. Co-existence of ADHD, autoimmune hypothyroidism and pituitary macroadenoma presenting in a behaviour clinic: a case report and brief review of the literature
  33. Virilizing para-adrenocortical adenoma associated with idiopathic-acquired generalized anhidrosis in an adolescent girl
  34. Concurrent occurrence of chronic lymphocytic thyroiditis with hypothyroidism and growth hormone deficiency in a Turner’s syndrome patient
  35. Patient report: sacral agenesis with hypopituitarism
  36. Meetings
  37. Meetings Calendar
Downloaded on 28.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem.2011.079/html
Scroll to top button